Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review

Hormone receptor-positive HER2-positive (HR+/HER2+) metastatic breast cancer (MBC) is a unique subtype of breast cancer. Most current guidelines recommend that combination regimens based on anti-HER2 therapy should be used as first-line treatment for HER2+ MBC, irrespective of HR status. Endocrine t...

Full description

Bibliographic Details
Main Authors: Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
advanced breast cancer
combination therapy
endocrine therapy
HR+/HER2+
human epidermal growth factor receptor 2-positive
hormone receptor-positive
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.975463/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.975463/full

Similar Items